Pulse Biosciences, Inc. (PLSE)

Market Cap	1.73B +57.8%
Revenue (ttm)	751,000
Net Income	-74.57M
EPS	-1.10
Shares Out	69.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	268,387
Open	24.45
Previous Close	24.74
Day's Range	24.00 - 25.73
52-Week Range	12.56 - 27.98
Beta	1.63
Analysts	Strong Buy
Price Target	30.00 (+20.0%)
Earnings Date	May 4, 2026

About PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 18, 2016
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: PLSE
• Website: https://www.pulsebiosciences.com

Analyst Summary

According to 2 analysts, the average rating for PLSE stock is "Strong Buy." The 12-month stock price target is $30.0, which is an increase of 20.00% from the latest price.

Price Target

$30.0

(20.00% upside)

Analyst Consensus: Strong Buy